|
Report Date : |
19.02.2014 |
IDENTIFICATION DETAILS
|
Name : |
ASPEN PHARMA INDUSTRIA FARMACÊUTICA LTDA |
|
|
|
|
Registered Office : |
Avenida Acesso Rodoviario S/Nº. Quadra 09, Módulo 1 Bairro TIMS,
29161-376 - Serra/ES |
|
|
|
|
Country : |
Brazil |
|
|
|
|
Date of Incorporation : |
27.01.1998 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Subject is engaged in the Manufacture of medicines. |
|
|
|
|
No. of Employees : |
400 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Brazil |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
BRAZIL - ECONOMIC OVERVIEW
Characterized by large and well-developed
agricultural, mining, manufacturing, and service sectors, Brazil's economy
outweighs that of all other South American countries, and Brazil is expanding
its presence in world markets. Since 2003, Brazil has steadily improved its
macroeconomic stability, building up foreign reserves, and reducing its debt
profile by shifting its debt burden toward real denominated and domestically
held instruments. In 2008, Brazil became a net external creditor and two
ratings agencies awarded investment grade status to its debt. After strong
growth in 2007 and 2008, the onset of the global financial crisis hit Brazil in
2008. Brazil experienced two quarters of recession, as global demand for
Brazil's commodity-based exports dwindled and external credit dried up.
However, Brazil was one of the first emerging markets to begin a recovery. In
2010, consumer and investor confidence revived and GDP growth reached 7.5%, the
highest growth rate in the past 25 years. Rising inflation led the authorities
to take measures to cool the economy; these actions and the deteriorating
international economic situation slowed growth to 2.7% in 2011, and 1.3% in
2012. Unemployment is at historic lows and Brazil's traditionally high level of
income inequality has declined for each of the last 14 years. Brazil's
historically high interest rates have made it an attractive destination for
foreign investors. Large capital inflows over the past several years have
contributed to the appreciation of the currency, hurting the competitiveness of
Brazilian manufacturing and leading the government to intervene in foreign
exchange markets and raise taxes on some foreign capital inflows. President
Dilma ROUSSEFF has retained the previous administration's commitment to
inflation targeting by the central bank, a floating exchange rate, and fiscal
restraint. In an effort to boost growth, in 2012 the administration implemented
a somewhat more expansionary monetary policy that has failed to stimulate much
growth.
|
Source
: CIA |
In absence of financials, no credit limit could be recommended.
ASPEN PHARMA
INDUSTRIA FARMACÊUTICA LTDA
|
MAIN ADDRESS: |
AVENIDA ACESSO RODOVIARIO S/Nº. QUADRA 09, MÓDULO 1 BAIRRO TIMS |
|
ZIP CODE/CITY: |
29161-376 - SERRA/ES |
|
|
|
|
PHONE: |
27 2121-9255 |
|
FAX: |
27 2121-9255 |
|
E-MAIL: |
fdrummond@aspenpharma.com.br |
|
WEB SITE: |
www.aspenpharma.com.br |
|
BRANCHES: |
|
|
|
|
|
ADDRESS: |
ESTRADA DOUTOR LORIVAL MARTINS, 926 A 928 - BAIRRO DONANA |
|
ZIP CODE/CITY: |
28110-000 CAMPO DOS GOYTACAZES/RJ |
|
PHONE: |
22 2101-2334 |
|
CNPJ: |
02.433.631/0007-15 |
|
|
|
|
ADDRESS: |
AVENIDA DAS AMÉRICAS, 3500 BLOCO 03, SALAS 401, 408 A 419 E 501 A 519
- BARRA DA TIJUCA |
|
ZIP CODE/CITY: |
22640-102 RIO DE JANEIRO/RJ |
|
PHONE: |
21 3544-6900 |
|
CNPJ: |
02.433.631/0009-87 |
|
MAIN ACTIVITIES: |
|
MANUFACTURE OF MEDICINES. |
|
LEGAL FORM: |
LIMITED
LIABILITY COMPANY |
|
|
|
|
INCORPORATION DATE: |
27/01/1998 |
|
REGISTER DATE: |
27/01/1998 |
|
BALANCE SHEET FILING DATE: |
31/12 |
|
TAX CONTRIBUTOR NUMBER(CNPJ): |
02.433.631/0001-20 |
|
STATE REGISTER: |
08.208.667-2 |
|
|
|
|
SHARE CAPITAL: |
R$ 349.852.681,00 |
|
BOARD OF
DIRECTORS: |
|
|
|
|
|
ALEXANDRE FRANCA |
MANAGER |
|
THE MANAGER IS AUTHORIZED TO SIGN ON BEHALF OF THE COMPANY. |
|
SHAREHOLDERS /
PARTNERS: |
|
|
|
|
|
PHARMALATINA HOLDINGS LMITED |
R$ 349.502.681,00 |
|
DISMEDICAL INTERNACIONAL LTD |
R$ 350.000,00 |
|
AFFILIATES / SUBSIDIARIES: |
|
|
|
|
|
ASPEN GROUP OVERVIEW |
|
|
THE SUBJECT WAS ESTABLISHED ON JANUARY 27, 1998 AS CELLOFARM LTDA. TO
BE ENGAGED IN THE SAID LINE OF BUSINESS. ON MAY 07, 2010 IT ADOPTED THE ABOVE
MENTIONED NAME AND UP TO DATE IT IS STILL OPERATING WITHIN THE GENERAL SCENE
REPORTED HEREIN. IN AUGUST 2003 THE SUBJECT TOOK OVER INFABRA FARMACEUTICA BRASILEIRA
LTDA, CNPJ 42.341.149/0001-84. TRADE NAME: CELLOFARM FARMACEUTICA. PARTNERS: PHARMALATINA HOLDINGS LMITED: (FORMERLY ADVANCED LAKEROSE LIMITED),
COMPANY ESTABLISHED ACCORDING TO THE LAWS OF CHIPRE, HEADQUARTERED AT 3,
THEMITOCLES DERVISM JULIA HOUSE, PC 1066, NICOSIA, CHIPRE, TAXPAYER'S
REGISTRATION UNDER 09.399.756/0001-20, REPRESENTED BY ITS ATTORNEY, MR.
EVANDRO BORGES PAIVA; DISMEDICAL INTERNACIONAL LIMITED: HEADQUARTERED AT MAURITIUS
INTERNATIONAL TRUST CO LTD, TAXPAYER'S REGISTRATION UNDER 11.637.671/0001-84. FURTHER DETAILS ARE SO FAR NOT KNOWN. WHEN CONTACTING THE SUBJECT WE INTERVIEWED MR. FABIO, FINANCIAL
DEPARTMENT, WHO INFORMED THAT WOULD NOT DISCLOSE ANY KIND OF INFORMATION
UNLESS THE INQUIRING PARTY'S NAME WAS DISCLOSED. IF IT IS POSSIBLE TO DISCLOSE THE NAME OF THE INTERESTED SUPPLIER OF THE
SUBJECT, WE MAY RESUME OUR CONTACTS AND TRY TO OBTAIN FURTHER INFORMATION. THE DATA CONTAINED HEREIN WERE OBTAINED FROM OUTSIDE SOURCES, OUR
DATABASE AND OFFICIAL. NO FURTHER DATA WAS AVAILABLE WITH SEVERAL SOURCES
USUALLY INVESTIGATED. |
|
PUBLIC INFORMATION: |
|
PROTESTS: |
|
5 PROTESTS,TOTAL AMOUNT R$
15.892,18 |
|
DETAILS OF LATEST PROTESTS: |
|
NOTARY OFFICE: |
DATE: |
VALUE: |
|
2º CARTÓRIO DE ES-SERRA |
31/05/2013 |
R$ 60,00 |
|
2º CARTÓRIO DE ES-SERRA |
14/01/2014 |
R$ 11.984,00 |
|
2º CARTÓRIO DE ES-SERRA |
08/07/2013 |
R$ 2.716,00 |
|
2º CARTÓRIO DE ES-SERRA |
27/02/2013 |
R$ 870,00 |
|
5º CARTÓRIO DE RJ-CAMPOS DE GOYTACAZES |
22/12/2010 |
R$ 262,18 |
|
LAWSUITS: |
|
|
|
|
DATE: |
COURT OF LAW: |
|
1 |
STATE LAWSUIT |
25/02/10 |
2ª VARA DE PE-RECIFE |
|
DUE TO THE SUBJECT'S LEGAL FORM, IT IS NOT OBLIGED TO PUBLISH THE
BALANCE SHEET INFORMATION. WHEN INTERVIEWING SOURCES AT THE SUBJECT COMPANY
DECLINED TO PROVIDE ANY KIND OF FINANCIAL INFORMATION. OUR INVESTIGATION THROUGH THE OUTSIDE SOURCES SHOWED NO FINANCIAL DATA
ABOUT THE SUBJECT. |
|
EXCHANGE RATE: |
|
|
US$ 1,00 = R$ 2,39 |
- OFFICIAL RATE |
|
COMMENTS ON THE
FINANCIAL INFORMATION: |
|
IN THE ABSENCE OF FINANCIAL INFORMATION NO COMMENTS CAN BE MADE ABOUT
THE SUBJECT'S CURRENT FINANCIAL STANDING. |
|
REAL ESTATE: |
NOT AVAILABLE
|
VEHICLES: |
NOT AVAILABLE
|
MACHINES: |
NOT AVAILABLE
INSURANCE:
|
NOT AVAILABLE. |
|
|
BRANCH/PHONE: |
|
|
BANCO DO BRASIL S/A |
3455-X / 21 3150-3003 |
|
|
BANCO BRADESCO S/A |
3378 / 21 3139-2253 |
|
|
REMARKS: IN BRAZIL THE BANKS ARE PROHIBITED BY LAW TO PROVIDE INFORMATION
OR ANY KIND OF COMMENTS ABOUT THEIR CLIENTS. DUE TO THIS LAW PROHIBITION WE
ARE UNABLE TO PROVIDE ANY BANKING DETAILS. ACCORDING TO THE CENTRAL BANK OF BRAZIL OFFICIAL REPORT, THE COMPANY
HAS NO RETURNED CHECKS UP TO DATE. (IN THE TERMS OF "CIRCULAR 1682
BRAZILIAN CENTRAL BANK"). |
|
SUBJECT IS ENGAGED IN THE MANUFACTURE OF MEDICINES. |
|
IMPORT AND
EXPORT: |
IMPORTS FROM:
|
INDIA, CHINA, ITALY, SOUTH KOREA AND TAIWAN. |
EXPORTS TO:
|
NOT AVAILABLE. |
|
MAIN CLIENTS: |
|
|
|
|
|
|
|
DOMESTIC
CLIENTS: |
|
|
|
DROGARIAS PACHECO S/A |
|
|
|
MEDNEWS PRODUTOS FARMACÊUTICOS LTDA |
|
|
|
STAFF: |
|
|
|
THE COMPANY HAS: 400 EMPLOYEE(S) |
|
THE SUBJECT WAS ESTABLISHED IN 1998. SO FAR IT HAS A CLEAR TRADE
HISTORY AND IT HAS A NORMAL PAYMENT BEHAVIOR. THE COMPANY HAS TRADE RELATIONS WITH SEVERAL SUPPLIERS IN BRAZIL. THE
SUPPLIERS EXTEND CREDIT FACILITIES TO THE SUBJECT IN TERMS AND AMOUNTS
ACCORDING TO THE COMPANY'S NEEDS AND SO FAR NO PAYMENT PROBLEMS ARE NOTED. THE LAWSUIT REPORTED IS NOT RELATED WITH TRADE DEBT. IT IS RELATED TO
TAX DEBT THAT FOR ANY REASON THE COMPANY HAS NOT YET PAID. NEVERTHELESS WE
POINT OUT THAT THE SAID LAWSUIT DOES NOT AFFECT THE COMPANY'S TRADE
REPUTATION. THE PROTESTS FOUND DO NOT AFFECT SUBJECT'S REPUTATION. |
|
MAIN SUPPLIERS: |
|
|
|
|
|
|
|
DOMESTIC
SUPPLIERS: |
|
PHONE: |
|
ANIDRO DO BRASIL EXTRAÇÕES LTDA |
|
21 3811-3512 |
|
BERTOLINI S/A |
|
|
|
CBE BANDEIRANTE DE EMBALAGENS S/A |
|
|
|
EMEFARMA RIO REPRES. LTDA |
|
|
|
FORNECEDORA COMERCIAL MAR LTDA |
|
|
|
GAME |
|
12 3133-7547 |
|
GIROFAC FOMENTO MERCL. LTDA |
|
|
|
GMU IND.DE PRODS.PLASTICOS E METALURGICOS LTDA |
|
|
|
LABORATÓRIO CENTROFLORA |
|
11 4193-2260 |
|
LABORATORIONEO QUIMICA COM.E IND.LTDA |
|
|
|
MACROMED COM.MATS.MEDICO E HOSPITALAR LTDA |
|
|
|
MILLENIUM COMERCIAL LTDA |
|
|
|
MINASFAC FOMENTO MERCL. LTDA |
|
|
|
NORTEC QUIMICA S/A |
|
21 3651-7314 |
|
PHARMACEUTICAL COM DE PRODS FARMACEUTICOS LTDA |
|
21 4221-2915 |
|
RAPIDAO COMERTA LOGISTICA TRANSP.S/A |
|
|
|
SANRISIL S/A IND E COM |
|
|
|
SARAPUÍ |
|
11 6115-3400 |
|
WIKA DO BRASIL IND.E COM.LTDA |
|
|
|
FOREIGN
SUPPLIERS: |
COUNTRY: |
|
|
QILU ANTIBIOTICS POHARMAC CO. LTD |
CHINA |
|
|
SHENZEN HAIBIN PHARMACEUTICAL CO. LTD |
CHINA |
|
|
STRIDES ARCOLAB LIMITED |
INDIA |
|
|
PAYMENT HISTORY: |
|
4 SUPPLIERS REPORTED PAYMENTS: |
|
TOTAL AMOUNT: R$ 107.880,00 |
|
|
|
AMOUNT OF INVOICES PAID: 19 |
|
TOTAL OF PROMPT PAYMENTS: 100% |
|
HIGHEST INVOICE: R$ 28.579,00 |
|
HIGHEST CREDIT: R$ 28.579,00 |
|
|
|
THE SUBJECT HAS BEEN IN BUSINESS SINCE 1998. UP TO DATE IT HAS CLEAR TRADE
HISTORY AND NO ADVERSE INFORMATION IS NOTED. BASED ON THE OVERALL DATA AVAILABLE THE SUBJECT MAY BE CONSIDERED FOR
NORMAL BUSINESS COMMITMENTS. CREDIT FACILITIES HOWEVER SHOULD BE GRANTED ON
FULLY SECURED TERMS ONLY DUE TO THE ABSENCE OF FINANCIAL DATA. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.12 |
|
|
1 |
Rs.103.93 |
|
Euro |
1 |
Rs.85.17 |
INFORMATION DETAILS
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists.
Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.